Bone Marrow Neoplasms: Clinical Trials

3 trials for Bone Marrow Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 terminated, 1 withdrawn. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Bone Marrow Neoplasms: new trials by email Literature Review of Bone Marrow Neoplasms trials Research Report on Bone Marrow Neoplasms

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm
Phase 4WithdrawnPharmaEssentia2026-08-012026-07-31
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
Hydroxyurea - Polycythemia Vera
Phase 4TerminatedNovartis Pharmaceuticals762023-07-282026-08-18
CINC424A2X01B Rollover Protocol
ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera
Phase 4Active not recruitingNovartis Pharmaceuticals2792015-03-052026-10-19

Narrower conditions

Polycythemia Vera (3)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Graft vs Host Disease (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Myeloproliferative Disorders (1)  ·  Primary Myelofibrosis (1)  ·  Thalassemia (1)

Broader conditions

Bone Marrow Diseases (3)  ·  Hematologic Diseases (3)  ·  Hematologic Neoplasms (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Myeloproliferative Disorders (2)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Congenital (1)  ·  Bronchial Diseases (1)  ·  Bronchiolitis (1)  ·  Bronchiolitis Obliterans (1)  ·  Bronchitis (1)

Interventions

Aspirin (1)  ·  Hydroxyurea (1)  ·  Panobinostat (1)  ·  Phlebotomy (1)  ·  ruxolitinib (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  PharmaEssentia (1)

Countries

Germany (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Chile (1)  ·  China (1)  ·  France (1)  ·  Greece (1)  ·  Hungary (1)  ·  India (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Lebanon (1)

NIH funding

2014 (1)